236 related articles for article (PubMed ID: 29753658)
1. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.
Pu SY; Xiao F; Schor S; Bekerman E; Zanini F; Barouch-Bentov R; Nagamine CM; Einav S
Antiviral Res; 2018 Jul; 155():67-75. PubMed ID: 29753658
[TBL] [Abstract][Full Text] [Related]
2. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.
Bekerman E; Neveu G; Shulla A; Brannan J; Pu SY; Wang S; Xiao F; Barouch-Bentov R; Bakken RR; Mateo R; Govero J; Nagamine CM; Diamond MS; De Jonghe S; Herdewijn P; Dye JM; Randall G; Einav S
J Clin Invest; 2017 Apr; 127(4):1338-1352. PubMed ID: 28240606
[TBL] [Abstract][Full Text] [Related]
3. BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals.
Pu S; Schor S; Karim M; Saul S; Robinson M; Kumar S; Prugar LI; Dorosky DE; Brannan J; Dye JM; Einav S
Antiviral Res; 2020 Dec; 184():104966. PubMed ID: 33137362
[TBL] [Abstract][Full Text] [Related]
4. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Neveu G; Ziv-Av A; Barouch-Bentov R; Berkerman E; Mulholland J; Einav S
J Virol; 2015 Apr; 89(8):4387-404. PubMed ID: 25653444
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing approaches to fight Dengue virus infection and related diseases.
Botta L; Rivara M; Zuliani V; Radi M
Front Biosci (Landmark Ed); 2018 Jan; 23(6):997-1019. PubMed ID: 28930586
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of prochlorperazine for use against dengue virus infection.
Simanjuntak Y; Liang JJ; Lee YL; Lin YL
J Infect Dis; 2015 Feb; 211(3):394-404. PubMed ID: 25028694
[TBL] [Abstract][Full Text] [Related]
7. Dengue Virus Evolution under a Host-Targeted Antiviral.
Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
[TBL] [Abstract][Full Text] [Related]
8. Drug repurposing of quinine as antiviral against dengue virus infection.
Malakar S; Sreelatha L; Dechtawewat T; Noisakran S; Yenchitsomanus PT; Chu JJH; Limjindaporn T
Virus Res; 2018 Aug; 255():171-178. PubMed ID: 30055216
[TBL] [Abstract][Full Text] [Related]
9. Repurposing the Antiemetic Metoclopramide as an Antiviral Against Dengue Virus Infection in Neuronal Cells.
Shen TJ; Hanh VT; Nguyen TQ; Jhan MK; Ho MR; Lin CF
Front Cell Infect Microbiol; 2020; 10():606743. PubMed ID: 33634036
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing of N-acetyl cysteine as antiviral against dengue virus infection.
Sreekanth GP; Panaampon J; Suttitheptumrong A; Chuncharunee A; Bootkunha J; Yenchitsomanus PT; Limjindaporn T
Antiviral Res; 2019 Jun; 166():42-55. PubMed ID: 30928439
[TBL] [Abstract][Full Text] [Related]
11. Dengue Virus-Infected Dendritic Cells, but Not Monocytes, Activate Natural Killer Cells through a Contact-Dependent Mechanism Involving Adhesion Molecules.
Costa VV; Ye W; Chen Q; Teixeira MM; Preiser P; Ooi EE; Chen J
mBio; 2017 Aug; 8(4):. PubMed ID: 28765218
[TBL] [Abstract][Full Text] [Related]
12. Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses.
Yu JS; Tseng CK; Lin CK; Hsu YC; Wu YH; Hsieh CL; Lee JC
Antiviral Res; 2017 Jan; 137():49-57. PubMed ID: 27847245
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
Franco EJ; Pires de Mello CP; Brown AN
Viruses; 2021 Apr; 13(5):. PubMed ID: 33925551
[TBL] [Abstract][Full Text] [Related]
14. A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity.
Moshiri J; Constant DA; Liu B; Mateo R; Kearnes S; Novick P; Prasad R; Nagamine C; Pande V; Kirkegaard K
mBio; 2020 Nov; 11(6):. PubMed ID: 33173007
[TBL] [Abstract][Full Text] [Related]
15. Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway.
Yu JS; Wu YH; Tseng CK; Lin CK; Hsu YC; Chen YH; Lee JC
Sci Rep; 2017 Mar; 7():45171. PubMed ID: 28338050
[TBL] [Abstract][Full Text] [Related]
16. AR-12 suppresses dengue virus replication by down-regulation of PI3K/AKT and GRP78.
Chen HH; Chen CC; Lin YS; Chang PC; Lu ZY; Lin CF; Chen CL; Chang CP
Antiviral Res; 2017 Jun; 142():158-168. PubMed ID: 28238876
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers.
Phumesin P; Junking M; Panya A; Yongpitakwattana P; Noisakran S; Limjindaporn T; Yenchitsomanus PT
Virus Res; 2019 Jan; 260():123-128. PubMed ID: 30503719
[TBL] [Abstract][Full Text] [Related]
18. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
Wan Y; Wu W; Wan Y; Li L; Zhang J; Chen X; Liu S; Yao X
Pharmacol Res; 2021 Aug; 170():105721. PubMed ID: 34116207
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of geraniin on dengue virus type-2 infected BALB/c mice.
Abdul Ahmad SA; Palanisamy UD; Khoo JJ; Dhanoa A; Syed Hassan S
Virol J; 2019 Feb; 16(1):26. PubMed ID: 30813954
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib and pyrrolidine dithiocarbamate decrease viral replication and cytokine production in dengue virus infected human monocyte cultures.
Duran A; Valero N; Mosquera J; Fuenmayor E; Alvarez-Mon M
Life Sci; 2017 Dec; 191():180-185. PubMed ID: 29055802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
